Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in
patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive
effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide
use in the treatment of PWS is limited to one case report by Cyganek et el (See attached
Citation). In this case report, the subject showed improvements in hemoglobin A1c and body
weight over 14 weeks.
The investigators plan to examine the use of liraglutide in a single subject with Prader
Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical
parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid
control.